Gentium Voluntarily Pulls NDA For Defibrotide; Shares Tumble
By Marie Powers
Friday, August 19, 2011
Shares of Gentium SpA slid Thursday after the company revealed it had voluntarily withdrawn the new drug application (NDA) for lead product candidate defibrotide.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.